Biological Therapy in Pediatric Inflammatory Bowel Disease: A Systematic Review

  title={Biological Therapy in Pediatric Inflammatory Bowel Disease: A Systematic Review},
  author={Domenico Corica and Claudio Romano},
  journal={Journal of Clinical Gastroenterology},
The incidence of inflammatory bowel disease (IBD) has increased steadily worldwide, both in adult and in children; approximately 25% of IBD patients are diagnosed before the age of 18. The natural history of IBD is usually more severe in children than in adults, and can be associated with linear growth impairment, delayed puberty onset, reduced bone mass index, malnutrition, and the need for surgery. Biological therapies, especially blocking tumor necrosis factor-&agr; (TNF&agr;), have… 

A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease

Current evidence on the indications, judicious use, effectiveness and safety of anti-TNF agents in paediatric IBD, specifically infliximab and adalimumab, are reviewed to provide personalized therapeutic strategies.

Antibiotics in pediatric inflammatory bowel diseases: a systematic review

Results of this systematic review of antibiotic use highlight the lack of evidence in pediatric IBD and more evidence is needed before widespread implementation in daily practice.

Paediatric Crohn’s Disease Patients Have Increased Inflammatory Markers Compared to Adult Patients prior to Biological Treatment

Background. Recent epidemiological studies in inflammatory bowel disease (IBD) indicate that paediatric onset of IBD (pIBD) more often requires biological therapy compared to adult onset of IBD

Treating children with inflammatory bowel disease: Current and new perspectives

Major advances have been achieved in monitoring the individual metabolism, toxicity and response to relevant medications in IBD including thiopurines and biologics includingThiopurine acting on novel mechanisms such as selective interference with lymphocyte trafficking are emerging treatment options.

Safety of Biological Therapy in Children With Inflammatory Bowel Disease.

The findings confirm a good safety profile of biologics in children with IBD, significantly linked to its immunogenicity and consequently with an impact on its efficacy and durability.

Inflammatory bowel disease and the lung in paediatric patients

The prevalence of inflammatory bowel disease (IBD) has increased over the past 20 years. Pulmonary involvement in paediatric IBD is rare but may be missed since the spectrum of symptoms is broad and

Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease

In this large paediatric cohort, children with clinical and/or endoscopic remission had significantly higher IFX exposure during maintenance therapy, which could provide a rationale for the use of proactive drug monitoring in children in order to improve long-term outcomes.

The use of biosimilars in paediatric inflammatory bowel disease

There are a growing number of postmarketing studies and real-life data that show reassuring comparable efficacy, safety and immunogenicity between CT-P13 and the reference Infliximab, indicating that biosimilars are increasingly regularly prescribed drugs in paediatric IBD.

Genetic Predictors of Long-term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease

Genotyping of these DNA variants before starting treatment may help to identify children who are long-term responders to anti-TNF drugs, and thus tailor treatment of pediatric IBD.



Inflammatory Bowel Disease in Children and Adolescents.

A contemporary overview of the epidemiologic features, pathogenesis, diagnosis, and management of IBD in children and adolescents, including ulcerative colitis and Crohn disease, is provided.

Mucosal healing in pediatric Crohn’s disease after anti-TNF therapy: a long-term experience at a single center

This is the first study reporting mucosal healing after ADA therapy in pediatric CD and compared with other pediatric studies, it reported similar clinical response rates and longer follow-up of patients.

Infliximab Therapy in Pediatric Patients 7 Years of Age and Younger

Although this is a limited study, there appears to be a trend for decreased sustained efficacy with IFX in this age group, particularly in children 5 years old and younger, when compared with the previously published literature in older children.

Inflammatory bowel disease in young people: The case for transitional clinics

Gastroenterologists should recognize that IBD is more complex when presenting in adolescence and the data support the creation of specific adolescent transitional clinics.

Rising Incidence of Inflammatory Bowel Disease Among Children: A 12-year Study

Data suggest an increase in the incidence of pediatric inflammatory bowel disease (IBD) among children with evidence of more CD than UC, and African Americans were predominantly diagnosed with CD.

Biological Therapy in a Pediatric Crohn Disease Population at a Referral Center

The study indicates that biological therapy is effective and safe in pediatric patients with CD in a longer follow-up period and the response to treatment was not influenced by the patients’ baseline characteristics or by the immunomodulator association.

Safety profile of biologic therapy in Polish paediatric patients with Crohn's disease

Biologic therapy with infliximab and/or adalimumab is generally well tolerated and safe, and does not cause any sAEs.

[Biological treatment of inflammatory bowel diseases in children in the years 2004-2013 in Poland].

Assessment of the use of biological drugs in treatment of inflammatory bowel disease in Poland found that in the last decade a significant increase on the number of children with Crohn's disease and ulcerative colitis treated with biological drugs was observed.

Malignancy and Mortality in Pediatric Patients with Inflammatory Bowel Disease: A Multinational Study from the Porto Pediatric IBD Group

Cancer and mortality in pediatric IBD are rare, but cumulative rates are not insignificant.

Infliximab Efficacy in Pediatric Ulcerative Colitis

Infliximab should be considered in the treatment of children with symptoms of acute moderate to severe ulcerative colitis, and patients receiving 6‐mercaptopurine had a better response to infliximab.